Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer
نویسندگان
چکیده
منابع مشابه
Adenoviral Vectors for Hemophilia Gene Therapy
Hemophilia is an inherited blood clotting disorder resulting from deficiency of blood coagulation factors. Current standard of care for hemophilia patients is frequent intravenous infusions of the missing coagulation factor. Gene therapy for hemophilia involves the introduction of a normal copy of the deficient coagulation factor gene thereby potentially offering a definitive cure for the bleed...
متن کاملTargeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas.
STUDY QUESTION Is targeted adenovirus vector, Ad-SSTR-RGD-TK (Adenovirus -human somatostatin receptor subtype 2- arginine, glycine and aspartate-thymidine kinase), given in combination with ganciclovir (GCV) against immortalized human leiomyoma cells (HuLM) a potential therapy for uterine fibroids? SUMMARY ANSWER Ad-SSTR-RGD-TK/GCV, a targeted adenovirus, effectively reduces cell growth in Hu...
متن کاملAdenoviral Gene Therapy for Ovarian Cancer
Helsinki 2004 Yliopistopaino The most beautiful thing we can experience is the mysterious. It is the source of all true art and science.
متن کاملAdenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
Gene therapy is an exciting novel approach for treating cancers resistant to currently available modalities. Treatment approaches are based on taking advantage of molecular differences between normal and tumor cells. Various strategies are currently in clinical development, with some promising early results reported with mutation compensation, molecular chemotherapy and replication competent vi...
متن کاملCollaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
Presently, we investigate the mechanisms whereby intratumoral expression of a cyclophosphamide-activating hepatic cytochrome P450 gene enhances therapeutic activity when cyclophosphamide is given on an every 6-day (metronomic) schedule. In P450-deficient 9L gliosarcomas grown in severe combined immunodeficient mice, metronomic cyclophosphamide substantially decreased tumor microvessel density a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Anti-Cancer Agents in Medicinal Chemistry
سال: 2014
ISSN: 1871-5206
DOI: 10.2174/18715206113139990309